Search Results for "aspirin"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for aspirin. Results 1 to 10 of 23 total matches.
See also: Aggrenox, Bayer, Ecotrin

Vazalore - A New Aspirin Formulation

   
The Medical Letter on Drugs and Therapeutics • May 02, 2022  (Issue 1649)
Vazalore - A New Aspirin Formulation ...
The FDA has approved an over-the-counter (OTC) liquid-filled capsule formulation of aspirin (Vazalore – PLx Pharma). The manufacturer has been heavily promoting Vazalore with claims of fast, predictable absorption and antiplatelet activity and improved gastrointestinal safety compared to existing OTC aspirin formulations.
Med Lett Drugs Ther. 2022 May 2;64(1649):70-1 |  Show IntroductionHide Introduction

Comparison Table: Some Nonopioid Analgesics for Pain (online only)

   
The Medical Letter on Drugs and Therapeutics • Mar 07, 2022  (Issue 1645)
in children $1.704 1.504 14.80 189.505,6 Salicylates Aspirin – generic Bayer (Bayer) 325 mg tabs; 500 ...
View the Comparison Table: Some Nonopioid Analgesics for Pain
Med Lett Drugs Ther. 2022 Mar 7;64(1645):e40-3 |  Show IntroductionHide Introduction

Nonopioid Drugs for Pain

   
The Medical Letter on Drugs and Therapeutics • Mar 07, 2022  (Issue 1645)
mg q6h or 650 mg q4h (max 4000 mg/day) Salicylates Aspirin – generic 325 mg tabs, 500 mg 325-650 ...
Nonopioid drugs can be used in the treatment of many nociceptive and neuropathic pain conditions. For severe pain, especially severe chronic cancer pain, use of opioids may be necessary. Noninvasive nonpharmacologic treatments, including physical and psychological therapies, have been shown to improve pain and function in patients with some common chronic pain conditions and are unlikely to cause serious harms. A multimodal approach to analgesic therapy can increase pain control while reducing opioid use and adverse effects.
Med Lett Drugs Ther. 2022 Mar 7;64(1645):33-40 |  Show IntroductionHide Introduction

Drugs for Treatment and Prevention of Venous Thromboembolism

   
The Medical Letter on Drugs and Therapeutics • Jul 25, 2022  (Issue 1655)
of thrombosis. Rivaroxaban, apixaban, dabigatran, or aspirin is recommended for prevention of VTE after knee ...
Anticoagulants are the drugs of choice for treatment and prevention of deep venous thrombosis (DVT) and pulmonary embolism (PE), collectively referred to as venous thromboembolism (VTE). US guidelines for treatment of VTE were updated in 2020 and 2021.
Med Lett Drugs Ther. 2022 Jul 25;64(1655):113-20 |  Show IntroductionHide Introduction

Iloprost (Aurlumyn) for Frostbite

   
The Medical Letter on Drugs and Therapeutics • Jul 22, 2024  (Issue 1707)
(12%) Half-life 20-30minutes Patients received rapid rewarming of frostbitten areas, aspirin, and IV ...
The FDA has approved Aurlumyn (Eicos Sciences), an IV formulation of the prostacyclin analog iloprost, to reduce the risk of digit amputation in adults with severe frostbite. Iloprost is the first drug to be approved by the FDA for treatment of severe frostbite; it has been used off-label for this indication in the EU and elsewhere for decades. In the US, iloprost is also available as an inhaled formulation (Ventavis) for treatment of pulmonary arterial hypertension.
Med Lett Drugs Ther. 2024 Jul 22;66(1707):114   doi:10.58347/tml.2024.1707b |  Show IntroductionHide Introduction

Comparison Table: Some Parenteral Anticoagulants for VTE (online only)

   
The Medical Letter on Drugs and Therapeutics • Jul 25, 2022  (Issue 1655)
transaminases, osteoporosis with long-term use Drug Interactions: Aspirin, NSAIDs, and other antiplatelet ...
View the Comparison Table: Some Parenteral Anticoagulants for VTE
Med Lett Drugs Ther. 2022 Jul 25;64(1655):e120-1 |  Show IntroductionHide Introduction

Apoaequorin (Prevagen) to Improve Memory

   
The Medical Letter on Drugs and Therapeutics • Nov 01, 2021  (Issue 1636)
aspirin ARBs anticoagulants ACE inhibitors Plavix rivaroxaban sacubitril statins valsartan Xarelto ...
A synthetic form of the protein apoaequorin is the active ingredient in the over-the-counter dietary supplement Prevagen (Quincy Bioscience), which is heavily marketed to improve memory.
Med Lett Drugs Ther. 2021 Nov 1;63(1636):175-6 |  Show IntroductionHide Introduction

Drugs Past Their Expiration Date

   
The Medical Letter on Drugs and Therapeutics • Jan 05, 2026  (Issue 1745)
ingredients had retained ≥90% of their original potency; aspirin retained ...
Healthcare providers are often asked if drugs can be used past their expiration date. Because of legal restrictions and liability concerns, manufacturers do not sanction such use and usually do not comment on the safety or effectiveness of their products beyond the date on the label. Since our last article on this subject, more data have become available.
Med Lett Drugs Ther. 2026 Jan 5;68(1745):5-7   doi:10.58347/tml.2026.1745c |  Show IntroductionHide Introduction

Prenatal Acetaminophen Use and Autism

   
The Medical Letter on Drugs and Therapeutics • Dec 08, 2025  (Issue 1743)
(including aspirin) around the time of conception or during pregnancy has been associated with an increased ...
Acetaminophen has been considered the drug of choice for treatment of fever and pain during pregnancy for decades, but a recent announcement by the US Department of Health and Human Services (HHS) has prompted discussion about its effects on fetal neurodevelopment and the risk of autism.
Med Lett Drugs Ther. 2025 Dec 8;67(1743):193-5   doi:10.58347/tml.2025.1743a |  Show IntroductionHide Introduction

Drugs for Gout

   
The Medical Letter on Drugs and Therapeutics • Oct 30, 2023  (Issue 1688)
reactions in aspirin-sensitive patients. Drug Interactions – NSAIDs can decrease the effectiveness ...
Drugs for gout are used to reduce the pain and inflammation of acute flares, decrease the frequency of exacerbations, and lower serum urate levels to prevent recurrent flares, development of tophi, and joint damage.
Med Lett Drugs Ther. 2023 Oct 30;65(1688):169-75   doi:10.58347/tml.2023.1688a |  Show IntroductionHide Introduction